Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02044822
Title Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gilead Sciences
Indications
Therapies
Age Groups: adult
Covered Countries USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DNK | CZE | BEL | AUT | AUS


No variant requirements are available.